Post by Biomed Valley Discoveries

Attending the American Society of Clinical Oncology (ASCO) Annual Meeting? Reach out if you’d like to meet with us at the conference! Our lead program, ulixertinib, is a highly selective, first-in-class inhibitor of ERK, the terminal node and master kinase of the mitogen-activated protein kinases (MAPK) pathway, one of the most prominently mutated pathways in cancer. We’re focused on unlocking the potential of ERK inhibition to deliver a new, durable treatment option for patients with MAPK pathway-driven cancers. Our clinical experience with the asset spans a broad range of cancers, including rare cancers and those that have been intractable to other treatment approaches. Find out more about ulixertinib here: https://lnkd.in/enwuqs9J #ASCO26 #CancerResearch #MAPK #ERKinhibition #Oncology